NCT03208036 Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness Status COMPLETED Phase NA
NCT03201757 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Status COMPLETED Phase PHASE3
NCT03198364 Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMI Status COMPLETED Phase NA
NCT03198078 Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia Status COMPLETED Phase PHASE3
NCT03197168 Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile Status COMPLETED Phase NA
NCT03192631 Financial Incentives to Improve Acceptance of Antipsychotic Injections Status UNKNOWN Phase NA
NCT03189810 Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia Status COMPLETED Phase NA
NCT03188133 Visual Information Processing in Schizophrenia Patients With Visual Hallucinations Status UNKNOWN Phase NA
NCT03187769 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Status COMPLETED Phase PHASE3
NCT03183947 Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms Status COMPLETED Phase NA
NCT03183609 Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG) Status COMPLETED Phase NA
NCT03179696 Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia Status COMPLETED Phase NA
NCT03172871 Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia Status COMPLETED Phase PHASE3
NCT03166098 The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders Status COMPLETED Phase N/A
NCT03164876 Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers. Status COMPLETED Phase PHASE1